Trial reportCancer medicine2026
The Effects of Lidocaine Patches on Post-Radiofrequency Ablation Pain in Patients With Hepatocellular Carcinoma.
Trial report in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05732181 (The Role of 5% Lidocaine Patches in the Pain Control of Hepatocellular Carcinoma Patients Receiving Radiofrequency Ablation), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of 5% Lidocaine Patches in the Pain Control of Hepatocellular Carcinoma Patients Receiving Radiofrequency Ablation: A Randomized, Double-blind, Placebo-controlled Study
Who cites it
2 citing papers in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
aimRadiofrequency ablation (RFA) is a standard treatment for patients with early-stage hepatocellular carcinoma (HCC). However, analgesics are often insufficient in mitigating post-RFA pain. The lidocaine patch is being investigated as an alternative for acute pain relief, though it has not yet been used for post-RFA pain. This study aims to evaluate the effect of lidocaine patches on post-RFA pain for patients with HCC.
methodsPatients undergoing RFA treatment were randomly assigned to an intervention group, receiving lidocaine patches (LP group), or a control group, receiving placebo patches (PP group). The primary endpoint was the Visual Analog Scale (VAS) pain score. The secondary endpoint was rescue analgesic use, quantified as the equivalent cumulative dose of residual morphine. Both were assessed concurrently every 4 h on the first day post-RFA.
resultsA total of 86 patients in the LP group and 68 patients in the PP group completed the study. Pain scores did not differ between the two groups at any time point. However, the equivalent cumulative dose of residual morphine was lower in the LP group compared to the PP group, with statistically significant differences at time points T4-T6 (p = 0.032, p = 0.018, and p = 0.032, respectively). After adjusting for confounding factors, multiple linear regression analysis yielded similar results.
conclusionsVAS pain scores, the primary endpoint, were not significantly different between the two groups. However, the objective equivalent cumulative dose of residual morphine was significantly reduced, implying that the lidocaine patch lowered residual systemic opioid exposure. We conclude that the lidocaine patch may be useful to reduce opioid use post-RFA.
trial registrationClinicalTrials.gov identifier: NCT05732181.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.